Literature DB >> 10227996

IL-4 inhibits the production of TNF-alpha and IL-12 by STAT6-dependent and -independent mechanisms.

M K Levings1, J W Schrader.   

Abstract

IL-4 promotes allergic responses and inhibits the production of proinflammatory cytokines by monocytes and macrophages. The promotion of allergic responses by IL-4 has been shown to be absolutely dependent on the transcription factor STAT6. We report here that the inhibitory effects of IL-4 on the production of TNF-alpha or IL-12 by macrophages had both STAT6-dependent and -independent components, depending on the stimuli. IL-4 failed to inhibit the release of TNF-alpha or IL-12 from STAT6 null macrophages stimulated with LPS alone. However, IL-4 still induced significant inhibition of the production of TNF-alpha and IL-12 from STAT6 null macrophages that were stimulated with the more physiologically relevant combination of LPS and IFN-gamma. These data show that STAT6 is required for the IL-4-mediated inhibition of the production of TNF-alpha and IL-12 stimulated by LPS alone, but that IL-4 also activates distinct, STAT6 independent mechanism(s) that inhibit the IFN-gamma-mediated enhancement of IL-12 and TNF-alpha production.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10227996

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB.

Authors:  Y Abu-Amer
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

2.  Differential IL-4/Stat6 activities correlate with differential expression of regulatory genes SOCS-1, SHP-1, and PP2A in colon cancer cells.

Authors:  Qin Yuan; Pin Dong Li; Ben Hui Li; Xian Zi Yang; Shuang Bing Xu; Xiao Hong Liu; Fu Xiang Zhou; Wen Jie Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-07       Impact factor: 4.553

3.  Use of transgenic parasites and host reporters to dissect events that promote interleukin-12 production during toxoplasmosis.

Authors:  David A Christian; Anita A Koshy; Morgan A Reuter; Michael R Betts; John C Boothroyd; Christopher A Hunter
Journal:  Infect Immun       Date:  2014-07-14       Impact factor: 3.441

4.  Regulation of lipopolysaccharide-induced interleukin-12 production by activation of repressor element GA-12 through hyperactivation of the ERK pathway.

Authors:  Shinji Saito; Motohiro Matsuura; Yoshikazu Hirai
Journal:  Clin Vaccine Immunol       Date:  2006-08

5.  Dissociation of endotoxin tolerance and differentiation of alternatively activated macrophages.

Authors:  Rajesh Rajaiah; Darren J Perkins; Swamy Kumar Polumuri; Aiping Zhao; Achsah D Keegan; Stefanie N Vogel
Journal:  J Immunol       Date:  2013-03-29       Impact factor: 5.422

6.  γδ T cells protect against LPS-induced lung injury.

Authors:  Fabian Wehrmann; James C Lavelle; Colm B Collins; Alex N Tinega; Joshua M Thurman; Ellen L Burnham; Philip L Simonian
Journal:  J Leukoc Biol       Date:  2015-10-01       Impact factor: 4.962

Review 7.  The potential for genetically altered microglia to influence glioma treatment.

Authors:  W Li; R M D Holsinger; C A Kruse; A Flügel; M B Graeber
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-09       Impact factor: 4.388

8.  Interleukin-10 targets p38 MAPK to modulate ARE-dependent TNF mRNA translation and limit intestinal pathology.

Authors:  D Kontoyiannis; A Kotlyarov; E Carballo; L Alexopoulou; P J Blackshear; M Gaestel; R Davis; R Flavell; G Kollias
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

Review 9.  Insulin signalling mechanisms for triacylglycerol storage.

Authors:  M P Czech; M Tencerova; D J Pedersen; M Aouadi
Journal:  Diabetologia       Date:  2013-02-27       Impact factor: 10.122

Review 10.  Theiler's virus infection: a model for multiple sclerosis.

Authors:  Emilia L Oleszak; J Robert Chang; Herman Friedman; Christos D Katsetos; Chris D Platsoucas
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.